Few medical fields have been transformed as rapidly as obesity medicine. Potent injectable medications can now strip away a fifth or more of body weight, digital coaching platforms deliver structured behavioral therapy through a phone screen, and flexible endoscopes can remodel the gastrointestinal tract without a single incision. Against this backdrop, an international group of bariatric surgeons has posed an uncomfortable but essential question in the International Journal of Obesity: in the era of remarkably effective pharmacotherapy, where exactly does metabolic bariatric surgery belong? Writing as a perspective piece rather than a trial report, Ricardo V. Cohen of Hospital Alemão Oswaldo Cruz in São Paulo, Paulina Salminen of Turku University Hospital, Jaime Ponce of the Weight Loss Center of Chattanooga, and Gerhard Prager of the Medical University of Vienna argue that the answer will shape the health of millions of patients for decades.
The authors ground their argument in a conceptual shift that has been gathering force since the Lancet Commission on the Definition of Clinical Obesity published its diagnostic framework in 2025. That commission drew a sharp line between preclinical obesity, a state of elevated risk in which organs still function normally, and clinical obesity, an established disease in which excess adiposity has begun to damage organs or limit physical function. This is not semantic hair-splitting. The distinction determines who needs what, and when. A patient with preclinical obesity may be well served by lifestyle support and, in some cases, medication to prevent progression. A patient with clinical obesity, whose joints, liver, heart, or metabolism are already failing under the burden of diseased fat tissue, may need interventions powerful enough to reverse established organ dysfunction, and quickly.
Cohen and his colleagues contend that failing to make this distinction carries four concrete harms. First, clinicians may delay escalating treatment for patients with clinical disease, the very group that benefits most from definitive therapy, while they wait to see whether a drug trial will succeed. Second, patients at the preclinical stage risk over-medicalization, receiving intensive and costly interventions they do not yet require. Third, when clinical trials enroll undifferentiated populations that mix these two states, the measured treatment effects become diluted, obscuring which therapy truly helps whom. Fourth, health systems with finite resources end up spending them inefficiently, funding interventions for people who would have done well with less while rationing them from people whose disease demands more. The positioning of surgery, in other words, is not an organizational detail but a question with direct clinical and economic stakes.
So what does the evidence say surgery can still deliver? The authors describe metabolic bariatric surgery as remaining among the most durable interventions available for clinical obesity. Operations such as sleeve gastrectomy and gastric bypass do more than restrict intake; they alter gut hormone signaling, appetite regulation, and glucose metabolism in ways that reduce adiposity, improve organ function, and, in a substantial fraction of patients, drive remission of obesity-related conditions including type 2 diabetes. Where a daily injectable drug works only for as long as it is taken, a surgical intervention produces anatomical and hormonal changes that persist. Long-term observational cohorts and randomized trials have documented weight loss and cardiometabolic benefit extending well beyond a decade after operation, a horizon no current pharmacotherapy has matched in head-to-head comparison.
The safety picture has also changed almost beyond recognition. The perspective emphasizes that over the past three decades surgical practice has evolved through technical refinement, standardized protocols, and systematic perioperative optimization. Contemporary bariatric surgery, supported by randomized clinical trials and mature long-term observational datasets, is described by the authors as a very safe therapeutic option for patients with advanced obesity and complex metabolic disease. Mortality rates for modern procedures are comparable to those of routine general surgery such as gallbladder removal, a statistic that surprises many clinicians whose mental image of the field was formed in an earlier era. The operations themselves have been refined laparoscopically and, increasingly, robotically, with shorter hospital stays and fewer complications than the open procedures of the 1990s.
Yet the authors do not dismiss the new pharmacotherapy; quite the opposite. Their argument is that glucagon-like peptide-1 receptor agonists and related agents are legitimate, powerful tools that belong inside a multimodal treatment framework, not rivals to be defeated. The framework they envision integrates behavioral, pharmacological, endoscopic, and surgical interventions, matched to disease stage and adapted over time. A patient might begin with structured lifestyle change and medication, add an endoscopic or pharmacological escalation if response is inadequate, and proceed to surgery when clinical obesity is established or when pharmacotherapy fails, is not tolerated, or is discontinued. Surgery, in this model, is not the option of last resort after everything else has failed, nor the reflexive first move. It is one instrument in a staged repertoire, deployed according to disease severity and patient goals.
The real-world behavior of patients on the new drugs adds urgency to this reasoning. A 2025 analysis in JAMA Network Open tracked discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among United States adults with overweight or obesity and documented substantial rates of patients stopping their medication, a pattern consistent with the well-known challenges of cost, supply, side effects, and waning motivation that accompany chronic injectable therapy. Weight regain after discontinuation is a predictable consequence of stopping an appetite-suppressing drug, because the underlying biology of obesity has not changed. The authors point to this fragility of pharmacological maintenance as precisely the scenario in which a durable intervention such as surgery retains its value, either as primary therapy for selected patients or as a rescue strategy after pharmacotherapy-induced weight loss plateaus or reverses. The International Federation for the Surgery of Obesity has already issued a formal statement, co-authored by several of the same authors, addressing how to position surgery after drug-induced weight loss in patients with clinical obesity.
Economics complicates the picture further. Two recent analyses cited in the perspective tackle the cost question directly. A matched cohort study published in Surgery for Obesity and Related Diseases in 2025 examined the cost-effectiveness of bariatric surgery and found grounds for arguing that surgical treatment pays for itself over time through reduced management of diabetes, cardiovascular disease, and other obesity complications. A separate cost comparison in Surgical Endoscopy asked where the break-even point lies between GLP-1 receptor agonists and surgery, a question that becomes pointed when a medication must be taken indefinitely at an annual cost that can exceed the one-time price of an operation within a few years. Health systems cannot fund everything for everyone, and the authors argue that stage-adapted care, in which expensive definitive therapy is reserved for established clinical disease, is the most defensible way to allocate limited resources while still offering earlier, less intensive support to those at risk.
Digital therapeutics form the final piece of the multimodal puzzle. A randomized controlled trial published in the same journal in 2026 evaluated a digital health application for weight management in people with obesity and reported six-month efficacy results, illustrating how digitally enabled care pathways are being woven into the therapeutic landscape alongside drugs and surgery. The authors view these tools not as competitors but as connective tissue: platforms that can extend behavioral support, monitor patients after surgery, flag weight regain, and coordinate escalation between treatment modalities. In an integrated system, a patient’s care might move fluidly between an app, a prescribing physician, an endoscopist, and a surgeon, with each step justified by measured disease status rather than by the habits or incentives of any single specialty.
The perspective’s ultimate message is a call for clinical discipline in a moment of therapeutic enthusiasm. Effective drugs have not made surgery obsolete, and surgery has not made drugs unnecessary; instead, the new diagnostic framework of clinical obesity gives clinicians a principled way to decide which patient needs which tool, and when. Mispositioning surgery, the authors warn, will delay definitive treatment for the sickest patients, while abandoning pharmacotherapy would deny many others a safer, less invasive path. The task for the coming decade is to build care pathways that treat obesity as the heterogeneous, chronic, progressive disease it is, matching the durability of the scalpel and the flexibility of the syringe to the stage of the disease in front of the clinician. In that matching, the authors conclude, lies the future of obesity medicine.
Subject of Research: Positioning of metabolic bariatric surgery within multimodal obesity care in the era of effective pharmacotherapy
Article Title: Where does surgery fit in the era of effective obesity pharmacotherapy? Positioning metabolic bariatric surgery within multimodal obesity care
Article References: Cohen, R. V., Salminen, P., Ponce, J., & Prager, G. (2026). Where does surgery fit in the era of effective obesity pharmacotherapy? Positioning metabolic bariatric surgery within multimodal obesity care. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02215-y
Image Credits: AI Generated
DOI: 10.1038/s41366-026-02215-y
Keywords: obesity, bariatric surgery, metabolic surgery, GLP-1 receptor agonists, pharmacotherapy, clinical obesity, Lancet Commission, multimodal treatment, digital health, cost-effectiveness, weight regain, International Journal of Obesity
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 26, 2026). Weight-Loss Drugs Reshaped Obesity Care, But Surgery Refuses to Fade. Scienmag. https://scienmag.com/weight-loss-drugs-reshaped-obesity-care-but-surgery-refuses-to-fade/
Ophelia Keating. “Weight-Loss Drugs Reshaped Obesity Care, But Surgery Refuses to Fade.” Scienmag, 26 September 2026, https://scienmag.com/weight-loss-drugs-reshaped-obesity-care-but-surgery-refuses-to-fade/. Accessed 26 September 2026.
Ophelia Keating. “Weight-Loss Drugs Reshaped Obesity Care, But Surgery Refuses to Fade.” Scienmag. September 26, 2026. https://scienmag.com/weight-loss-drugs-reshaped-obesity-care-but-surgery-refuses-to-fade/
Copy citation Download RIS
Tags: bariatric surgeryclinical obesityclinical vs preclinical obesityCost-effectivenessdigital behavioral therapy for obesitydigital healthendoscopic bariatric proceduresevolution of obesity medicinefuture of obesity managementGLP-1 receptor agonistsimpact of pharmacotherapy on obesity careinjectable obesity drugsInternational Journal of ObesityLancet Commissionmetabolic surgerymultimodal treatmentobesityobesity diagnostic frameworksobesity treatment advancementspharmacotherapyrole of metabolic bariatric surgerysurgical vs. non-surgical obesity interventionsWeight loss medicationsweight regain
